Inovio Pharmaceuticals Inc (Nasdaq:INO) announced the appointment of Scott M. White, M.D. as Vice President, Clinical Development – Infectious Diseases. Dr. White will be responsible for advancing Inovio’s infectious disease portfolio of DNA immunotherapies and vaccines through clinical trials to commercialization. He will report to Dr. Mark Bagarazzi, Inovio’s Chief Medical Officer.
Inovio is advancing a robust clinical pipeline of therapies and vaccines for infectious diseases including hepatitis B and C, HIV, influenza, Ebola and other tropical diseases.
Dr. White joins Inovio from GlaxoSmithKline where he spent more than a decade in positions of increasing responsibility leading global infectious disease clinical development programs. His most recent position was Senior Director and Project Physician Leader for skin-related infections. He led multiple programs within the Infectious Diseases Therapy Area with international responsibilities from clinical trials to business and market development. In his GSK career, Dr. White built strong relationships with the FDA, EMEA and other regulatory and government agencies. Most notable was his leadership in the design and implementation of a pioneering European antibacterial clinical development network through a public private partnership between the European Commission and EFPIA (European Federation of Pharmaceutical Industries and Associations).
Dr. J. Joseph Kim, President & CEO of Inovio, said, “Scott will bring to Inovio his global experience and expert judgment in advancing infectious disease therapies and vaccines through numerous country regulatory agencies. As we ramp up clinical development of our rich pipeline, Inovio has now attracted three cancer and infectious disease opinion leaders this year. Their counsel as M.D.’s will be invaluable to Inovio as we move our vaccines and immunotherapies closer to market.”
Dr. White, who earned his M.D. at the Pennsylvania State University College of Medicine, was an Edward J. Wing Fellow in Infectious Diseases at the University of Pittsburgh Medical Center. He also was assistant professor atBaylor College of Medicine and The University of Pittsburgh School of Medicine as well as lead author of numerous scientific publications. (Original Source)
Shares of Inovio Pharmaceuticals closed yesterday at $8.56 . INO has a 1-year high of $13.04 and a 1-year low of $6.33. The stock’s 50-day moving average is $7.50 and it’s 200-day moving average is $9.39.
On the ratings front, Inovio has been the subject of a number of recent research reports. In a report issued on March 16, Brean Murray Carret analyst Jonathan Aschoff reiterated a Buy rating on INO, with a price target of $20, which implies an upside of 133% from current levels. Separately, on March 12, H.C. Wainwright’s Yi Chen initiated coverage with a Buy rating on the stock and has a price target of $17.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Jonathan Aschoff and Yi Chen has a total average return of 19.3% and -0.4% respectively. Aschoff has a success rate of 69.5% and is ranked 40 out of 3533 while Chen has a success rate of 50.0% and is ranked 2640
Inovio Pharmaceuticals, Inc. is a biomedical company, engaged in the development of next-generation vaccines to prevent or treat cancers and chronic infectious diseases.